Alembic Pharmaceuticals reports resilient Q4 FY26 performance with 4 Percent revenue growth and 29 Percent profit rise

Mumbai, May 15 : Alembic Pharmaceuticals Limited reported its consolidated financial results for the fourth quarter and year ended 31^st March 2026.

Financial Highlights for Q4 FY26

• Revenue from operations increased by 4% YoY to Rs.1,848 Cr.
• Profit After Tax at Rs. 203 Cr, up 29% YoY
• EBITDA pre R&D increased by 8% YoY to Rs. 455 Cr; Pre R&D EBITDA margin stood at 25%

Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said,

 “Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments. We delivered revenue growth across key segments while maintaining healthy pre-R&D operating margins. During the quarter, we marked our entry into the Branded Business in the US, beginning with the launch of Pivya, opening a new avenue for long-term value creation.”

Operational Highlights

India Branded Business

• India Branded Business delivered 4% YoY growth, reaching Rs 568 Cr. in revenue for the quarter.
• Gynaecology, Gastrology, Ophthalmology and Animal healthcare segments demonstrated encouraging performance during the quarter.
• 2 new products were introduced during the quarter.

International Business

• US Formulation grew by 11% to Rs. 564 Cr.
• 6 Launches in the US market during the quarter.
• Ex-US Generics recorded revenue of Rs. 369 Cr.
• 4 ANDA approvals received during the quarter

Entry into US Branded Pharmaceuticals market

During the quarter, the Company launched its US branded business through Alembic Therapeutics, its step-down wholly owned subsidiary, with the commercial launch of Pivya. This marks the first step in Alembic’s strategy to build a focused branded specialty portfolio in the US.

Pivya represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women. The segment has seen limited new product introductions for more than a decade, creating an opportunity for a clinically established therapy with a strong safety and efficacy profile.